| A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential | 2019/02/07 | English | 152 |
| Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs | 2004/01/01 | English | 150 |
| Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus | 2013/05/14 | English | 150 |
| Induction of CYP3A4 by Efavirenz in Primary Human Hepatocytes: Comparison With Rifampin and Phenobarbital | 2004/11/01 | English | 150 |
| Epidemiology of Diabetes | 2004/04/01 | English | 148 |
| Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects | 1983/04/01 | English | 146 |
| Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite | 1992/08/01 | English | 146 |
| Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants | 2009/06/01 | English | 143 |
| Cardiovascular Consequences of Marijuana Use | 2002/11/01 | English | 143 |
| The Absolute Bioavailability of Oral Melatonin | 2000/07/01 | English | 143 |
| Co‐Enzyme Q10: A New Drug for Cardiovascular Disease | 1990/07/01 | English | 139 |
| Assessing pain intensity with the visual analog scale: A plea for uniformity | 2014/01/23 | English | 136 |
| Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal | 2004/06/01 | English | 136 |
| Sex, Race, and Smoking Impact Olanzapine Exposure | 2008/02/01 | English | 135 |
| The Role of TNFα in Ulcerative Colitis | 2007/08/01 | English | 134 |
| Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8 | 2005/01/01 | English | 133 |
| Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis | 2007/03/01 | English | 133 |
| Adulteration by Synthetic Therapeutic Substances of Traditional Chinese Medicines in Taiwan | 1997/04/01 | English | 131 |
| Reducing Medication Errors and Increasing Patient Safety: Case Studies in Clinical Pharmacology | 2003/07/01 | English | 131 |
| Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin | 2006/09/01 | English | 131 |
| Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline | 2006/05/01 | English | 130 |
| AmBisome (Liposomal Amphotericin B): A Comparative Review | 1998/07/01 | English | 130 |
| Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies | 2011/08/01 | English | 129 |
| Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers | 2010/08/01 | English | 129 |
| Gender Differences in Adverse Drug Reactions | 1998/11/01 | English | 129 |
| Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials | 2009/09/01 | English | 129 |
| Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study | 2013/12/11 | English | 129 |
| Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis | 2009/02/01 | English | 127 |
| Model Appropriateness and Population Pharmacokinetic Modeling | 2003/06/01 | English | 127 |
| Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers | 2004/02/01 | English | 126 |